The predictive value of thymidylate synthase (TS) for clinical sensitivity to pemetrexed-containing chemotherapy in patients with non-small cell lung cancer (NSCLC) remains controversial. The gene discussed is TYMS; the disease is non-small cell lung carcinoma.